Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market?
So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes off.
Overview
Humans are very bad at taking medications. By some estimates, adherence to long-term chronic medication treatment plans is only around 50%. This is a big issue for GLP-1 weight-loss drugs, which must be taken for life and as often as daily. Pfizer (NYSE: PFE) is betting that making a more convenient option will give it a leg up on the competition.
Pfizer has a problem when it comes to GLP-1 weight-loss drugs. Novo Nordisk (NYSE: NVO) was the first to market with its Wegovy shot. Eli Lilly's (NYSE: LLY) Zepbound and Mounjaro came out next, but proved more effective and quickly became the industry-leading GLP-1 weight-loss drugs. Pfizer gave up on its own option and was forced to go back to the drawing board by acquiring a company with a more attractive GLP-1 drug candidate.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.